Critical Comparison: Estrella Immunopharma (ESLA) vs. Its Rivals

Estrella Immunopharma (NASDAQ:ESLA) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Estrella Immunopharma to related companies based on the strength of its earnings, dividends, analyst recommendations, institutional ownership, profitability, valuation and risk.

Analyst Recommendations

This is a summary of current recommendations and price targets for Estrella Immunopharma and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	0	0	1	0	3.00
Estrella Immunopharma Competitors	2047	5577	14306	317	2.58

Estrella Immunopharma currently has a consensus target price of $16.00, suggesting a potential upside of 1,484.16%. As a group, “Biological products, except diagnostic” companies have a potential upside of 115.13%. Given Estrella Immunopharma’s stronger consensus rating and higher probable upside, equities analysts plainly believe Estrella Immunopharma is more favorable than its rivals.

Risk and Volatility

Estrella Immunopharma has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Estrella Immunopharma’s rivals have a beta of -4.60, meaning that their average share price is 560% less volatile than the S&P 500.

Valuation and Earnings

This table compares Estrella Immunopharma and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Estrella Immunopharma	N/A	-$7.31 million	-3.88
Estrella Immunopharma Competitors	$581.03 million	-$70.44 million	3.80

Estrella Immunopharma’s rivals have higher revenue, but lower earnings than Estrella Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Estrella Immunopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	-195.77%	-157.28%
Estrella Immunopharma Competitors	-2,185.76%	-161.46%	-40.62%

Institutional & Insider Ownership

0.3% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 15.2% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Estrella Immunopharma beats its rivals on 7 of the 13 factors compared.

About Estrella Immunopharma

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.